- Home
- A-Z Publications
- Current Drug Targets
- Previous Issues
- Volume 16, Issue 5, 2015
Current Drug Targets - Volume 16, Issue 5, 2015
Volume 16, Issue 5, 2015
-
-
Pathophysiology of Erectile Dysfunction
Authors: Hotaka Matsui, Nikolai A. Sopko, Johanna L. Hannan and Trinity J. BivalacquaErectile dysfunction (ED) is a major health problem as the population ages. Basic science research for the last two decades has expanded the knowledge on ED and identified several key molecular changes associated with the pathogenesis of ED, including nitric oxide (NO) / cyclic guanosine monophosphate (cGMP) / protein kinase G (PKG) pathway, RhoA/Rho-associated protein kinase (ROCK) signaling pathway, reactive oxyg Read More
-
-
-
PDE-5 Inhibitors: Clinical Points
Authors: Michael Doumas, Antonios Lazaridis, Niki Katsiki and Vasilios AthyrosErectile dysfunction is usually of vascular origin and is frequently encountered in men with cardiovascular disease. The introduction of phosphodiesterase-5 inhibitors has revolutionized the management of patients with erectile dysfunction. Currently available phosphodiesterase-5 inhibitors have distinct pharmacokinetic and pharmacodynamic properties, thus permitting for tailoring sexual therapy according to pati Read More
-
-
-
Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Authors: Inger Stallmann-Jorgensen and R. Clinton WebbIntroduction: Erectile dysfunction (ED) has reached epidemic proportions not expected to abate because of population aging and chronic diseases that accompany advanced age. Vasculopathy is a main cause, but damage to penile innervation also underlies many cases of ED. Phosphodiesterase inhibitor therapies do not help all men with ED, making the search for novel therapeutic drug and treatment targets Read More
-
-
-
There is a Link Between Erectile Dysfunction and Heart Failure: It could be Inflammation
More LessThe rates of erectile dysfunction (ED) in heart failure (HF) are extremely high. Limited capacity of patients with HF to exercise and coronary artery disease are considered to be the main causative mechanisms. Both HF and ED are associated with increased levels of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL- 8). The increased levels of proinflammatory cytoki Read More
-
-
-
Penile Rehabilitation After Radical Prostatectomy
Authors: David Jacques Cohen and Sidney GlinaErectile dysfunction (ED) is the main and most frequent side effect after radical prostatectomy. Also, ED is the primary impact factor for quality of life after radical prostatectomy. ED post radical prostatectomy is mainly due to lesions in the neurovascular bundles which can occur by partial or total sectioning, by stretching (the most common), or by thermal lesion of the nervous fibers, leading to a condition called “neuropraxia” Read More
-
-
-
Molecular Pathophysiology of Cavernous Nerve Injury and Identification of Strategies for Nerve Function Recovery After Radical Prostatectomy
Authors: Emmanuel Weyne, John Mulhall and Maarten AlbersenDespite nerve-sparing techniques, erectile dysfunction remains commonly observed after radical prostatectomy due to neuropraxia to the cavernous nerves during surgery. Preservation and rehabilitation of erectile function after radical prostatectomy remains challenging and many men stay undertreated with the current armory of therapies available in clinical practice. In this article we provide a comprehensive ove Read More
-
-
-
Molecular Pathophysiology of Priapism: Emerging Targets
Authors: Uzoma A. Anele, Belinda F. Morrison and Arthur L. BurnettPriapism is an erectile disorder involving uncontrolled, prolonged penile erection without sexual purpose, which can lead to erectile dysfunction. Ischemic priapism, the most common of the variants, occurs with high prevalence in patients with sickle cell disease. Despite the potentially devastating complications of this condition, management of recurrent priapism episodes historically has commonly involved reactive tre Read More
-
-
-
Management of Peyronie's Disease after Collagenase (Xiaflex:®)
Authors: Amjad Alwaal, Ahmed Aly Hussein, Uwais B. Zaid and Tom F. LueAlthough the prevalence of Peyronie’s disease (PD) is reported to be 3-9% in men, the true prevalence is likely higher due to under-reporting. Many treatment modalities have been described for PD with varying degrees of success. In this article, we review and summarize the current literature pertaining to all pharmacotherapies (oral, intralesional, iontophoresis, and topical) and minimally invasive treatments available for PD (v Read More
-
-
-
Immobilization and Detection Strategies for Multifunctional Glycochips
Authors: Gangliang Huang, Xinya Mei, Qilin Tang and Xin ChenGlycochips can be used to map the carbohydrate-protein interactions in high-throughput manner. Carbohydrates are immobilized on the support surface by covalent or noncovalent binding. The immobilization strategies for glycochips were summarized herein. In addition, some recently developed techniques for detection of carbohydrate-protein interactions were also involved.
-
-
-
Targeting the Multifaceted HuR Protein, Benefits and Caveats
The RNA-binding protein (RBP) HuR is one of the most widely studied regulators of the eukaryotic posttranscriptional gene expression and it plays a physiological role in mediating the cellular response to apoptotic, proliferating and survival stimuli. Following physiological or stress stimuli, HuR protein binds to Adenylate-Urydinilate rich elements (AREs) generally contained in the 3’UTR of transcripts, then it shuttles from the nucl Read More
-
-
-
Regulating the Beta Cell Mass as a Strategy for Type-2 Diabetes Treatment
Authors: Imane Song, Christo Muller, Johan Louw and Luc BouwensThe incidence of type 2 diabetes (T2D) increases dramatically worldwide and has created an enormous health care burden. Obesity, dyslipidemia and insulin resistance are major risk factors for the development of T2D, but the major factor leading to the disease is failure of the insulin-producing beta cell mass to compensate for increasing insulin demands of the body. Progression of the disease further diminishes the b Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cdt
Journal
10
5
false
en
